Evidence map›Paper›PMID 37024408›Full record

Observational studyVaccine2023

The added effect of non-pharmaceutical interventions and lifestyle behaviors on vaccine effectiveness against severe COVID-19 in Chile: A matched case-double control study.

Cinthya Urquidi, Emilio Santelices, Anne J Lagomarcino, María Teresa Valenzuela, Nicolás Larrañaga, Emilio Gonzalez, Axel Pavez, Amanda Wosiack, Marcela Maturana, Paulina Moller and 3 more

Abstract readObservational StudyMulticenter Study
In one paragraph

Observational study in Vaccine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Cinthya UrquidiDepartamento de Epidemiología y Estudios en Salud, Facultad de Medicina, Universidad de Los Andes, Chile, Monseñor Álvaro del Portillo 1245, Las Condes, Santiago, Chile.
Emilio SantelicesEscuela de Salud Pública, Facultad de Medicina, Universidad de Chile, Av. Independencia 939, Independencia, Santiago, Chile.
Anne J LagomarcinoDirección de Innovación, Facultad de Medicina, Universidad de Chile, Av. Independencia 1027, Independencia, Santiago, Chile.
María Teresa ValenzuelaDepartamento de Epidemiología y Estudios en Salud, Facultad de Medicina, Universidad de Los Andes, Chile, Monseñor Álvaro del Portillo 1245, Las Condes, Santiago, Chile.
Nicolás LarrañagaHospital El Carmen Dr. Luis Valentín Ferrada, Camino a Rinconada 1201, Avenida El Olimpo, Maipú, Santiago, Chile.
Emilio GonzalezHospital de Urgencia Asistencia Pública (HUAP), Curicó 345, Santiago, Chile; Universidad del Desarrollo, Facultad de Medicina Clinica Alemana, Avenida La Plaza 680, Las Condes, Santiago, Chile.
Axel PavezHospital de Urgencia Asistencia Pública (HUAP), Curicó 345, Santiago, Chile.
Amanda WosiackHospital de Urgencia Asistencia Pública (HUAP), Curicó 345, Santiago, Chile.
Marcela MaturanaIndependent consultant.
Paulina MollerCesfam Dr. José Eduardo Ahués, Independencia 2200, Maipú, Santiago, Chile.
Juan Pablo TorresDirección de Innovación, Facultad de Medicina, Universidad de Chile, Av. Independencia 1027, Independencia, Santiago, Chile; Departamento de Pediatría Oriente, Facultad de Medicina, Universidad de Chile, Av. Antonio Varas 360, Providencia, Santiago, Chile.
Sergio MuñozDepartamento de Salud Pública - CIGES, Facultad de Medicina, Universidad de La Frontera, Av. Francisco Salazar 01145, Temuco, Chile.
Miguel O'Ryan GPrograma de Microbiología y Micología, Instituto de Ciencias Biomédicas, Facultad de Medicina, Av. Independencia 1027, Universidad de Chile, Independencia, Santiago, Chile; Instituto de Sistemas Complejos de Ingeniería (ISCI), Universidad de Chile, República 695, Santiago, Chile. Electronic address: moryan@uchile.cl.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWorld Health Organization approved vaccines have demonstrated relatively high protection against moderate to severe COVID-19. Prospective vaccine effectiveness (VE) designs with first-hand data and population-based controls are nevertheless rare. Neighborhood compared to hospitalized controls, may differ in compliance to non-pharmacuetical interventions (NPI) compliance, which may influence VE results in real-world settings. We aimed to determine VE against COVID-19 intensive-care-unit (ICU) admission using hospital and community-matched controls in a prospective design.

methodsWe conducted a multicenter, observational study of matched cases and controls (1:3) in adults ≧18 years of age from May to July 2021. For each case, a hospital control and two community controls were matched by age, gender, and hospital admission date or neighborhood of residence. Conditional logistic regression models were built, including interaction terms between NPIs, lifestyle behaviors, and vaccination status; the model's β coefficients represent the added effect these terms had on COVID-19 VE.

resultsCases and controls differed in several factors including education level, obesity prevalence, and behaviors such as compliance with routine vaccinations, use of facemasks, and routine handwashing. VE was 98·2% for full primary vaccination and 85·6% for partial vaccination when compared to community controls, and somewhat lower, albeit not significantly, compared to hospital controls. A significant added effect to vaccination in reducing COVID-19 ICU admission was regular facemask use and VE was higher among individuals non-compliant with the national vaccine program, and/or tonroutine medical visits during the prior year.

conclusionVE against COVID-19 ICU admission in this stringent prospective case-double control study reached 98% two weeks after full primary vaccination, confirming the high effectiveness provided by earlier studies. Face mask use and hand washing were independent protective factors, the former adding additional benefit to VE. VE was significantly higher in subjects with increased risk behaviors.

Indexed as

COVID-19Vaccine EfficacyAdultCase-Control StudiesChileCOVID-19 VaccinesHumansLife StyleCOVID-19 VaccinesCOVID-19Non-pharmacological interventionRisk factorsSARS-Cov-2Vaccine effectiveness

Identifiers

PMID37024408
PMCPMC10067460

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.